Bladder Cancer Breakthrough: IL-23's Double-Edged Sword
"New research reveals how Interleukin-23 (IL-23) can either fuel or fight bladder cancer, depending on its concentration. Uncover the future of targeted treatments."
Bladder cancer remains a significant health challenge worldwide. While treatments have advanced, the search for more targeted and effective therapies continues. Recent research has shed light on the complex role of Interleukin-23 (IL-23), a molecule known to influence inflammation and immunity, in bladder cancer progression.
IL-23 is a type of protein called a cytokine, and is at the center of immune responses. Prior studies have shown that IL-23 is found in higher levels in bladder cancer tissues compared to normal tissues. However, the functional role of IL-23 has remained largely unknown, and the impact it has on cancer development.
A new study explores this duality, demonstrating that IL-23 can either promote or suppress bladder cancer cell growth, migration, and invasion, all depending on its concentration. This discovery opens new doors for understanding bladder cancer and designing more precise treatment strategies.
Bladder Cancer’s Global Burden
Bladder cancer is the ninth most common cancer worldwide, according to a 2026 global overview that examines geographic differences in incidence and mortality using national estimates, population-based cancer registries, and vital statistics. The SEER Cancer Stat Facts resource provides bladder cancer statistics by sex, race, calendar year, and age, and for selected analyses by stage and histology. The American Cancer Society’s key-statistics page reports expected new cases and deaths for the year, but the supplied source snippet does not give those figures. A 2018 article describes research into IL-23’s concentration-dependent effects on bladder cancer cell growth, migration, and invasion.
Milestones in Understanding and Treatment
Cancer Research UK identifies a 2004 milestone: its scientists highlighted high levels of the E2F3 gene as a potential marker of aggressive bladder cancer that could flag cancers needing more urgent treatment. The supplied 2022 review says platinum-based chemotherapy was the first-choice treatment for advanced bladder cancer and that immune checkpoint inhibitors had changed the therapeutic landscape of many solid tumors over the preceding decade. A separate 2025 study describes Droller’s proposal that bladder cancer can develop through varied pathways, producing distinct tumor types that require different clinical management. A 2024 study set out to examine changes in IL-17A and IL-23 levels in bladder cancer patients and selected benign urological diseases.
IL-23: Friend or Foe in Bladder Cancer?
The study, published in Oncology Reports, investigated the effects of IL-23 on bladder cancer cells. Researchers found that low concentrations of IL-23 (20 ng/ml) stimulated T24 bladder cancer cells. This stimulation led to:
- Increased cell proliferation (growth)
- Enhanced migration (movement to new areas)
- Greater invasion (penetration into surrounding tissues)
- Epithelial-mesenchymal transition (EMT), a process that allows cancer cells to become more aggressive and mobile
IL-23’s Concentration-Dependent Immune Effects
The supplied sources describe IL-23 as having different associations with bladder tumor progression depending on its expression level: one reports that low expression promotes progression while higher expression suppresses it, and another says low concentrations promoted progression while high expression was associated with a better prognosis. A review of immunotherapy for bladder tumors offers a proposed mechanism for the high-concentration effect: IL-23 can bind IL-23r and IL-12Rβ1, activating STAT4 and increasing IFN-γ, which activates NK cells and TH1 T cells with anti-tumor effects. These findings describe research-level observations and a proposed mechanism, rather than establishing a treatment strategy.
The Future of Bladder Cancer Treatment: Personalized Approaches
This research highlights the importance of understanding the specific conditions within the tumor microenvironment. IL-23 is not simply a pro-cancer or anti-cancer molecule; its effects depend on its concentration and potentially other factors within the tumor.
Biological Complexity and Recurrence
A review of bladder cancer challenges and future directions describes a nonsystematic review of recent English-language PubMed articles focused on current challenges and future directions. A 2025 review says bladder cancer presents treatment challenges because of its intricate biological features and high recurrence rates. It also notes developments in immunotherapy and targeted therapies in recent years, while framing treatment innovation as an ongoing need.
Recurrence, Surveillance, and Survival Differences
A 2026 research abstract reports 82,000 new bladder cancer cases and 17,000 deaths annually in the United States, and says bladder cancer represents 5% of U.S. malignancies. It reports that most tumors are non-muscle invasive, recurrence is common, and long-term surveillance is required. The abstract gives five-year survival rates of 96% for non-invasive disease, 70% for localized disease, 34% for regional disease, and 5% for metastatic disease. A separate 2026 source estimates 613,791 new bladder and urinary tract cancer cases worldwide in 2022 and says urothelial cancers comprise 90% of bladder cancers.
The study suggests that future bladder cancer treatments could be tailored to individual patients based on their IL-23 expression levels. For example:
<ul> <li>Patients with low IL-23: Therapies that block alternative pro-tumor pathways might be beneficial.</li> <li>Patients with high IL-23: Boosting the immune system's ability to recognize and eliminate cancer cells could be the focus.</li> </ul>